Professor & Chair
Texas Tech University Health Sciences Center
Lubbock, TX, United States
Dr. Afzal A. Siddiqui holds the highest academic rank of Grover E. Murray Professor that Texas Tech University Health Sciences Center (TTUHSC) bestows on its faculty. He is the Chair of the Department of Immunology & Molecular Microbiology at the TTUHSC-School of Medicine. He has earned his B.Sc. (Hons), M.Sc. and M. Phil. degrees from the Aligarh Muslim University in India and his Ph.D. degree from the University of Western Ontario in Canada. His professional training is from the Centers for Disease Control and Prevention, Morehouse College, University of Illinois College of Medicine, and Harvard University School of Public Health. He is a recipient of Fulbright Research and Teaching Scholarship for Southeast Asia.
Dr. Siddiqui has authored over 100 research papers, book chapters/reviews and articles. He serves on several Editorial Boards of scientific journals and has served as peer-reviewer for over 100 international journals. He has served on numerous NIAID and NIH study sections. He serves as a consultant to US FDA. He has reviewed grants for Ministry of Labor, Health and Social Policies, Republic of Italy; Romanian National Council for Scientific Research; Medical Research Council, Australia; Czech Science Foundation; and Netherlands Organization for Scientific Research.
Dr. Siddiqui has developed a vaccine against schistosomiasis, called SchistoShield® which has received patents in the USA and internationally. Schistosomiasis is a debilitating disease with which 252 million people are currently infected and an additional 779 million are at risk of acquiring the infection in 79 countries.
Phase 1 human clinical trials of SchistoShield® in USA have just been completed at the Kaiser Permanente Washington Health Research Institute (NIAID’s Infectious Diseases Clinical Research Consortium). Phase 1b/2a trials in Africa (Madagascar, Burkina Faso) are ongoing and are funded through Bill & Melinda Gates Foundation, European Union/Horizon 2020 and RIGHT Foundations grants. SchistoShield® is concurrently optimized in schistosome human challenge infection model (Funded by Wellcome Trust) in Europe (The Netherlands) and Africa (Uganda).
Disclosure(s): No financial relationships to disclose
263 - Take It in the Arm: New and Evolving Vaccines and Strategies
Saturday, October 19, 2024
3:15 PM – 4:30 PM US PT
613 - A new vaccine for an ancient plague: development of a schistosomiasis vaccine
Saturday, October 19, 2024
3:40 PM – 4:05 PM US PT